文献速递前列腺癌

可解释人工智能前列腺穿刺决策支持工具的开发与验证

Development and validation of an explainable artificial intelligence-based decision-supporting tool for prostate biopsy.
PubMed 文献 · BJU Int · 2020-08-04

本研究使用3791例患者数据开发并验证基于可解释人工智能(XAI)的前列腺癌(PCa)和临床显著前列腺癌(csPCa)风险计算器。采用极端梯度提升算法和Shapley值确定特征重要性,最终PCa模型AUC为0.869(95%CI 0.844-0.893),csPCa模型AUC为0.945(95%CI 0.927-0.963)。

要点

  • 基于XAI的前列腺穿刺风险计算器可预测PCa和csPCa概率。
  • PCa模型AUC为0.869,csPCa模型AUC为0.945。
  • PSA、游离PSA、年龄、前列腺体积等为重要预测参数。

核心结论

  • 成功开发并验证了用于前列腺穿刺前计算PCa和csPCa概率的XAI决策支持工具。

研究设计与样本

  • 使用3791例患者数据开发并验证风险计算器,数据分为开发集和验证集。
  • 开发集采用极端梯度提升算法,五折交叉验证及超参数调优,基于Shapley值确定特征重要性。
  • 开发集2843例,测试集948例。

主要发现

  • 1216例(32.7%)诊断为PCa,562例(14.8%)诊断为csPCa。
  • 最终PCa模型AUC为0.869(95%CI 0.844-0.893)。
  • csPCa模型AUC为0.945(95%CI 0.927-0.963)。
  • PCa模型重要参数包括PSA水平、游离PSA水平、年龄、前列腺体积(移行区和总体)、超声低回声病灶和睾酮水平。
  • 既往穿刺次数与csPCa风险无关,但与PCa风险负相关。

临床怎么用

  • 可用于前列腺穿刺前计算PCa和csPCa概率,辅助临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To develop and validate a risk calculator for prostate cancer (PCa) and clinically significant PCa (csPCa) using explainable artificial intelligence (XAI). PATIENTS AND METHODS: We used data of 3791 patients to develop and validate the risk calculator. We initially divided the data into development and validation sets. An extreme gradient-boosting algorithm was applied to the development calculator using five-fold cross-validation with hyperparameter tuning following feature selection in the development set. The model feature importance was determined based on the Shapley value. The area under the curve (AUC) of the receiver operating characteristic curve was analysed for each validation set of the calculator. RESULTS: Approximately 1216 (32.7%) and 562 (14.8%) patients were diagnosed with PCa and csPCa. The data of 2843 patients were used for development, whereas the data of 948 patients were used as a test set. We selected the variables for each PCa and csPCa risk calculation according to the least absolute shrinkage and selection operator regression. The AUC of the final PCa model was 0.869 (95% confidence interval [CI] 0.844-0.893), whereas that of the csPCa model was 0.945 (95% CI 0.927-0.963). The prostate-specific antigen (PSA) level, free PSA level, age, prostate volume (both the transitional zone and total), hypoechoic lesions on ultrasonography, and testosterone level were found to be important parameters in the PCa model. The number of previous biopsies was not associated with the risk of csPCa, but was negatively associated with the risk of PCa. CONCLUSION: We successfully developed and validated a decision-supporting tool using XAI for calculating the probability of PCa and csPCa prior to prostate biopsy.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Suh J, Yoo S, Park J, et al. Development and validation of an explainable artificial intelligence-based decision-supporting tool for prostate biopsy. BJU Int. 2020. PMID: 32455477. doi:10.1111/bju.15122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。